Drugs / engineered nasal cartilage graft
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01242618 | Oct 2010 → Feb 2013 | skin carcinoma | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | engineered nasal cartilage graft | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01242618 ↗ |
| Modality | Cell therapy | “autologous nasal chondrocytes expanded in vitro and cultured in a collagen Type I/III scaffold” NCT01242618 ↗ |
| Route | Other | “implantation of engineered nasal cartilage grafts in the alar lobule” NCT01242618 ↗ |